ArticleThoracic cancer2022

Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations.

Mio Kanbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.